DDN May 2017 DDN March2018 | Página 6

Session 1 Healthy connections The day’s first session kicked off by looking at making effective connections with health services ‘W e’ve got a lot of work to do developing pathways to make sure that the health of service users is taken as seriously as that of everyone else,’ CGL’s director of nursing, Stacey Smith, told Get Connected delegates. ‘We have a fantastic opportunity to make a massive impact.’ In terms of tackling hepatitis C, it was important that drug treatment services realised that they held a huge cohort of people who could benefit from testing and treatment, she said, and CGL had launched its own successful hepatitis C strategy to reduce the number of service users who become ill or die prematurely as a result of hep C infection. ‘We have current and previous injectors in our system, and the treatment landscape has significantly improved for drug users with hepatitis C. It’s a two-way process – we need to work with the NHS, and they need to work with us. If we can match up people’s drug treatment with their hepatitis C treatment, think of the fantastic things we can do.’ Drug services held enormous amounts of invaluable data, she told the conference. ‘That’s data about people who may have been diagnosed ten or 15 years ago, as well as data on people coming in now.’ Where previously hepatitis C treatment had been ‘painful, hard, long and not always successful’, that was no longer the case, and it was vital to make sure that service users were aware of this. ‘We need to let people know that it’s not about interferon any more. Wouldn’t it be fantastic if every service user who walked into a drug service demanded to be tested and treated?’ Services were perfectly placed to play a crucial role in the drive towards the complete stACey smIth ‘Universal credit has made it very hard to access housing.’ 6 | drinkanddrugsnews | March 2018 eradication of hepatitis C, she said, and were also equipped with vital skills in areas like motivational interviewing and contingency management. ‘We know there are people out there who are still injecting, so we need proper use of harm reduction. We need to look at re-engaging with needle exchanges and talking about what harm reduction really means.’ Key to this were areas such as optimum prescribing, the development of evidence-based models with treatment on site, and proactive partnerships with bodies like the Hepatitis C Trust, the NHS and service user groups. ‘We have it within our capability to eliminate hepatitis C within drug and alcohol services,’ she told delegates, and CGL now had four models running across the country that matched up people’s treatment and prescriptions. ‘Let’s get innovative – whichever way works for you, do it. The opportunity we have now is massive.’ R ecovery champion Alesha Watkins told the conference how she had initially been offered testing and treatment after accessing a needle exchange in Northamptonshire in 2009. ‘A couple of weeks later I was advised I had hep C, but I wasn’t ready to engage,’ she said. She continued to inject, ‘After seven years of having hepatitis C, I stand here today free of any virus.’ AleshA WAtkIns www.drinkanddrugsnews.com